Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Imagem de Miniatura
Arquivos
art_MARSO_Efficacy_and_Safety_of_Degludec_versus_Glargine_in_2017.PDF (316.44 KB)
Citações na Scopus
475
Tipo de produção
article
Data de publicação
2017
Editora
MASSACHUSETTS MEDICAL SOC
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
MARSO, Steven P.
MCGUIRE, Darren K.
ZINMAN, Bernard
POULTER, Neil R.
EMERSON, Scott S.
PIEBER, Thomas R.
PRATLEY, Richard E.
HAAHR, Poul-Martin
LANGE, Martin
BROWN-FRANDSEN, Kirstine
Autor de Grupo de pesquisa
DEVOTE Study Grp
Editores
Coordenadores
Organizadores
Citação
NEW ENGLAND JOURNAL OF MEDICINE, v.377, n.8, p.723-732, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-to-target, event-driven cardiovascular outcomes trial. The primary composite outcome in the time-to-event analysis was the first occurrence of an adjudicated major cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) with a prespecified noninferiority margin of 1.3. Adjudicated severe hypoglycemia, as defined by the American Diabetes Association, was the prespecified, multiplicity-adjusted secondary outcome. RESULTS Of the patients who underwent randomization, 6509 (85.2%) had established cardiovascular disease, chronic kidney disease, or both. At baseline, the mean age was 65.0 years, the mean duration of diabetes was 16.4 years, and the mean (+/- SD) glycated hemoglobin level was 8.4 +/- 1.7%; 83.9% of the patients were receiving insulin. The primary outcome occurred in 325 patients (8.5%) in the degludec group and in 356 (9.3%) in the glargine group (hazard ratio, 0.91; 95% confidence interval, 0.78 to 1.06; P<0.001 for noninferiority). At 24 months, the mean glycated hemoglobin level was 7.5 +/- 1.2% in each group, whereas the mean fasting plasma glucose level was significantly lower in the degludec group than in the glargine group (128 +/- 56 vs. 136 +/- 57 mg per deciliter, P<0.001). Prespecified adjudicated severe hypoglycemia occurred in 187 patients (4.9%) in the degludec group and in 252 (6.6%) in the glargine group, for an absolute difference of 1.7 percentage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority). Rates of adverse events did not differ between the two groups. CONCLUSIONS Among patients with type 2 diabetes at high risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidence of major cardiovascular events.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/31251
Referências
  1. [Anonymous], 2001, J Postgrad Med, V47, P199
  2. [Anonymous], 2015, TRESIBA SUMMARY PROD
  3. [Anonymous], 2015, TRESIBA PRESCRIBING
  4. Dailey G, 2011, DIABETES TECHNOL THE, V13, DOI 10.1089/dia.2011.0019
  5. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2008, DIAB MELL EV CARD RI
  6. Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431
  7. Frier BM, 2011, DIABETES CARE, V34, pS132, DOI [10.2337/dc11.-s220, 10.2337/dc11-s220]
  8. Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743
  9. Gerstein HC, 2012, NEW ENGL J MED, V367, P319, DOI 10.1056/NEJMoa1203858
  10. Graveling Alex J, 2009, Prim Care Diabetes, V3, P131, DOI 10.1016/j.pcd.2009.08.007
  11. Heise T, 2012, DIABETES OBES METAB, V14, P859, DOI 10.1111/j.1463-1326.2012.01627.x
  12. Heise T, 2004, DIABETES, V53, P1614, DOI 10.2337/diabetes.53.6.1614
  13. Heise T, 2017, DIABETES OBES METAB, V19, P3, DOI 10.1111/dom.12782
  14. Li J, 2016, CLIN THER, V38, P372, DOI 10.1016/j.clinthera.2015.12.006
  15. Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3
  16. Marso SP, 2016, AM HEART J, V179, P175, DOI 10.1016/j.ahj.2016.06.004
  17. Miller ME, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5444
  18. Munnee K, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003006
  19. Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987
  20. Ratner RE, 2013, DIABETES OBES METAB, V15, P175, DOI 10.1111/dom.12032
  21. Schnell O, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0456-8
  22. Seaquist ER, 2013, DIABETES CARE, V36, P1384, DOI 10.2337/dc12-2480
  23. Turner RC, 1998, LANCET, V352, P837
  24. Wittes J., 2013, P 4 SEATTL S BIOST C, P95
  25. Wittes J, 2009, CIRCULATION, V119, P912, DOI 10.1161/CIRCULATIONAHA.108.836601
  26. World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
  27. Wysham C, 2016, DIABETOLOGIA, V59, pS43
  28. Zoungas S, 2010, NEW ENGL J MED, V363, P1410, DOI 10.1056/NEJMoa1003795

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03